Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.27AUD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$1.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,735,202
52-wk High
$3.41
52-wk Low
$1.17

Chart for

About

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $602.37
Shares Outstanding(Mil.): 470.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS

* MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS

Nov 10 2017

BRIEF-Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment

* Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment Source text for Eikon: Further company coverage:

Sep 28 2017

BRIEF-Mesoblast posts FY loss attributable of $76.8 mln

* FY loss attributable to owners of co $76.8 million versus loss of $4.1 million Source text for Eikon: Further company coverage:

Aug 29 2017

BRIEF-Mesoblast completes institutional entitlement offer for capital raise

* Completes institutional entitlement offer for fully underwritten A$50.7 million capital raise

Aug 28 2017

BRIEF-Mesoblast announces capital raising

* Fully underwritten accelerated non-renounceable entitlement offer to raise A$50.7m

Aug 24 2017

BRIEF-Mesoblast seeks trading halt

* Seeking trading halt pending an announcement to ASX by company regarding a fully underwritten capital raising Source text for Eikon: Further company coverage:

Aug 24 2017

BRIEF-Mesoblast Ltd files ‍​for $180 million American depositary shares representing ordinary shares

* Mesoblast Ltd - files ‍​for $180 million American depositary shares representing ordinary shares Source text: (http://bit.ly/2u50ziE) Further company coverage:

Jul 10 2017

UPDATE 1-Australia's Mesoblast posts narrower quarterly loss, rise in R&D costs

May 25 Australian regenerative medicine maker Mesoblast Ltd on Thursday posted a narrower quarterly loss but booked a rise in research and development costs.

May 25 2017

CORRECTED-Australia's Mesoblast flags "going concern" doubts

May 25 Australian regenerative medicine maker Mesoblast Ltd said on Thursday it needed new funding from a third party partner or from capital raising to continue in business as it had cash reserves of $69.1 million.

May 25 2017

Earnings vs. Estimates